Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

THOMSON REUTERS
10 Dec 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10